search
Back to results

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

Primary Purpose

Neovascular Age-related Macular Degeneration

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Sponsored by
Olix Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neovascular Age-related Macular Degeneration focused on measuring Neovascular age-related macular degeneration, OLX10212, siRNA, intravitreal injection, safety and tolerability, preliminary efficacy

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Men and women ≥50 years of age Primary subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea, as evidenced by FA in the study eye CNV must be ≥50% of the total lesion size in the study eye ETDRS BCVA score ranging from 20/60 to 20/400 in the study eye Clear ocular media and adequate pupillary dilation (able to dilate pupil to ≥4 mm using standard mydriatics) in the study eye to permit good stereoscopic fundus photography Retinal thickness ≥200 μm in the macular region of the study eye as measured by SD-OCT, and active neovascular AMD, in the opinion of the Investigator Willing, committed, and able to return for all clinic visits and complete all study-related procedures Able to read (or if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or by a family member), understand, and willing to sign the informed consent form Exclusion Criteria: Any prior systemic treatment for neovascular AMD in either eye, except dietary supplements or vitamins or systemic anti-VEGF therapy, or planned use at any time during the study Any prior treatment in the study eye with another investigational agent to treat neovascular AMD within 6 months prior to Day 0 or planned use at any time during the study Prior treatment with anti-VEGF agents as follows: Anti-VEGF therapy in the study eye within 4 weeks prior to Day 0 Anti-VEGF therapy in the study eye at any time to which there was no response, as defined by the presence of at least 1 of the following conditions: (1) persistent (plasma) fluid exudation, (2) unresolved or new hemorrhage, and (3) progressive lesion fibrosis Anti-VEGF therapy in the fellow eye with an investigational agent (not FDA approved, unless it is bevacizumab) within 3 months prior to Day 0 (prior treatment with an FDA approved anti-VEGF therapy in the fellow eye is allowed at any time) Systemic anti-VEGF therapy, investigational or FDA approved, within 3 months prior to Day 0 or planned use at any time during the study Scar or fibrosis in the study eye involving >50% of the total lesion size Retinal pigment epithelial tears or rips in the study eye involving the macula within 6 months prior to Day 0 History of any vitreous hemorrhage in the study eye within 4 weeks prior to Day 0 Presence of other causes of CNV in the study eye, including pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis Clinical evidence of moderate or severe diabetic retinopathy, diabetic macular edema, or any other inflammatory or occlusive vascular disease affecting the retina (other than AMD) in either eye History of stage ≥2 macular hole in the study eye Any prior intraocular or periocular surgery on the study eye within 3 months prior to Day 0 (lid surgery is allowed if it took place at least 1 month prior to Day 0 and is unlikely to interfere with OLX10212 injection). Prior vitrectomy in the study eye, surgery for retinal detachment in the study eye, and prior trabeculectomy or other filtration surgery in the study eye are not permitted at any time Uncontrolled glaucoma (defined as IOP ≥25 mmHg despite treatment with antiglaucoma medication) in the study eye Glaucoma in the study eye requiring treatment with 3 or more antiglaucoma medications Active intraocular inflammation or history of uveitis in either eye Presence or history of ocular or periocular infection in either eye within 2 weeks prior to Day 0 Presence of scleromalacia in the study eye Aphakia or absence of posterior capsule in the study eye (unless due to yttrium aluminum garnet [YAG] posterior capsulotomy) Prior therapeutic radiation in the region of the study eye or planned use at any time during the study Significant media opacities, including cataract, in the study eye that, in the opinion of the Investigator, could interfere with visual acuity, assessment of safety, or fundus photography Any concurrent intraocular condition in the study eye (eg, cataract) that, in the opinion of the Investigator, could (1) require either medical or surgical intervention during the 24- or 32-week study period (Part A or Part B, respectively), (2) increase the risk to the patient beyond what is to be expected from standard intraocular injection procedures, or (3) otherwise interfere with the injection procedure or efficacy or safety evaluation History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications Participation as a patient in any clinical study or prior systemic or ocular treatment with an investigational agent within 12 weeks prior to Day 0 Prior systemic or intraocular treatment with long-acting steroids within 6 months prior to Day 0 or planned use at any time during the study History of allergy to povidone iodine Known allergy to fluorescein sodium for injection in angiography Unwillingness among females who are pregnant, breastfeeding, or of childbearing potential to practice adequate contraception throughout the study. Adequate contraceptive measures include oral contraceptives (stable use for ≥2 cycles prior to Day 0), intrauterine device, Depo-Provera® (Pfizer, Inc., New York) or Norplant System® (Pfizer, Inc., New York) implants, bilateral tubal ligation, vasectomy, and condom or diaphragm plus contraceptive sponge, foam, or jelly. A female is considered to be of childbearing potential unless she is premenstrual, 1 year postmenopausal, or 3 months post-surgical sterilization. All females of childbearing potential, including those with post-tubal ligation, must have a negative urine pregnancy test result at Day 0 and every 4 weeks as outlined in the Schedule of Activities. A negative serum pregnancy test must be obtained at Screening.

Sites / Locations

  • California Retina ConsultantsRecruiting
  • University RetinaRecruiting
  • The Retina InstituteRecruiting
  • Ophthalmic Consultants of the Capital RegionRecruiting
  • Texas Retina ConsultantsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Part A 94.3 μg/eye

Part A 235.8 μg/eye

Part A 471.5 μg/eye

Part A 707.3 μg/eye

Part A 895.9 μg/eye

Part B Low dose

Part B Medium dose

Part B High dose

Arm Description

study eye treated with 94.3 μg of OLX10212

study eye treated with 235.8 μg of OLX10212

study eye treated with 471.5 μg of OLX10212

study eye treated with 707.3 μg of OLX10212

study eye treated with 895.9 μg of OLX10212

study eye treated with up to 3 intravitreal low dose injections of OLX10212 each 28 days apart

study eye treated with up to 3 intravitreal medium dose injections of OLX10212 each 28 days apart

study eye treated with up to 3 intravitreal high dose injections of OLX10212 each 28 days apart

Outcomes

Primary Outcome Measures

Best-corrected visual acuity (BCVA)
Visual acuity using an ETDRS chart
Intraocular pressure (IOP)
Millimeters of mercury (mmHg)
Slit lamp
Anterior segment of the eye examination
Fundus examination
Posterior segment of the eye examination
Spectral-domain optical coherence tomography (SD-OCT)
Evaluation of retinal characteristics
Fluorescein angiography (FA)
Evaluation of retinal vasculature

Secondary Outcome Measures

Full Information

First Posted
November 10, 2022
Last Updated
September 21, 2023
Sponsor
Olix Pharmaceuticals, Inc.
Collaborators
Trial Runners, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05643118
Brief Title
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
Official Title
Evaluation of the Safety and Tolerability of OLX10212 in Patients With Neovascular Age-Related Macular Degeneration
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 4, 2023 (Actual)
Primary Completion Date
November 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Olix Pharmaceuticals, Inc.
Collaborators
Trial Runners, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase 1, multicenter, open-label, single- and multi-dose, dose-escalating study of OLX10212 in patients with neovascular age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B. Part A is a single ascending dose study, and Part B is a multiple ascending dose study. The primary objective is to evaluate the safety and tolerability of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD. The exploratory objectives are to evaluate the preliminary efficacy of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD, and to evaluate the pharmacokinetics (PK) of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD.
Detailed Description
This is a Phase 1, multicenter, open-label, single- and multi-dose, dose escalation study to evaluate the safety, tolerability, and preliminary efficacy of OLX10212 in the treatment of age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B. Part A is a single ascending dose study, i.e. participants will receive one intravitreal injection of OLX10212 at different dose levels and Part B is a multiple ascending dose study, i.e. participants will receive up to three intravitreal injections of OLX10212. Up to 48 individuals with AMD will be invited to participate in this study. The mechanism of action of OLX10212 holds promise to treat AMD by improving inflammation in the retina which is typically observed in patients with AMD. This is the first time OLX10212 is used in patients with AMD. Safety and tolerability of OLX10212 will be assessed via detailed ophthalmologic evaluations, vital signs, and clinical laboratory testing. In addition, plasma concentrations of OLX10212 will be measured and evaluations of the therapeutic effects of OLX10212 will be performed. Part A uses a dose-ascending, sequential design to evaluate up to five doses of OLX10212, starting with the lowest dose of OLX10212 in a 50-μL injection. Up to six patients will be enrolled at each dose level. Each of the enrolled patients will receive a single intravitreal administration of OLX10212. The safety and tolerability evaluation period will encompass the first 14 days following OLX10212 administration. The effects of OLX10212 will be observed up to 24-weeks after injection. Based on the safety and tolerability evaluation, a decision will be made whether or not to increase the dose to the next higher dose levels for the subsequent patient cohorts. Therefore, a total of up to 30 patients (up to 5 dose levels and up to 6 patients/dose level) will be enrolled in Part A of this study. Part B of this study uses a dose-ascending, sequential design to evaluate 3 dose levels of OLX10212 (low, medium, and high), starting with the low dose. The dose levels for Part B will be determined after completion of Part A. Up to six patients will be enrolled at each dose level. Each of the enrolled patients will receive a total of up to three intravitreal injections of OLX10212, each four weeks apart (Week 0, Week 4, and Week 8). The safety and tolerability evaluation period will encompass the first 12 weeks following the first OLX10212 administration (ending 4 weeks following the third OLX10212 administration), during which safety and tolerability will be assessed. In addition, the plasma concentrations of OLX10212 will be measured and therapeutic effects will be evaluated. A total of up to 18 patients with AMD (3 dose levels and up to 6 patients/dose level) will be invited to participate in Part B of this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neovascular Age-related Macular Degeneration
Keywords
Neovascular age-related macular degeneration, OLX10212, siRNA, intravitreal injection, safety and tolerability, preliminary efficacy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part A 94.3 μg/eye
Arm Type
Experimental
Arm Description
study eye treated with 94.3 μg of OLX10212
Arm Title
Part A 235.8 μg/eye
Arm Type
Experimental
Arm Description
study eye treated with 235.8 μg of OLX10212
Arm Title
Part A 471.5 μg/eye
Arm Type
Experimental
Arm Description
study eye treated with 471.5 μg of OLX10212
Arm Title
Part A 707.3 μg/eye
Arm Type
Experimental
Arm Description
study eye treated with 707.3 μg of OLX10212
Arm Title
Part A 895.9 μg/eye
Arm Type
Experimental
Arm Description
study eye treated with 895.9 μg of OLX10212
Arm Title
Part B Low dose
Arm Type
Experimental
Arm Description
study eye treated with up to 3 intravitreal low dose injections of OLX10212 each 28 days apart
Arm Title
Part B Medium dose
Arm Type
Experimental
Arm Description
study eye treated with up to 3 intravitreal medium dose injections of OLX10212 each 28 days apart
Arm Title
Part B High dose
Arm Type
Experimental
Arm Description
study eye treated with up to 3 intravitreal high dose injections of OLX10212 each 28 days apart
Intervention Type
Genetic
Intervention Name(s)
OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Other Intervention Name(s)
OLX10212
Intervention Description
Clear colorless solution dissolved in 1X PBS and injected intravitreally
Primary Outcome Measure Information:
Title
Best-corrected visual acuity (BCVA)
Description
Visual acuity using an ETDRS chart
Time Frame
28 days after last dose administration
Title
Intraocular pressure (IOP)
Description
Millimeters of mercury (mmHg)
Time Frame
28 days after last dose administration
Title
Slit lamp
Description
Anterior segment of the eye examination
Time Frame
28 days after last dose administration
Title
Fundus examination
Description
Posterior segment of the eye examination
Time Frame
28 days after last dose administration
Title
Spectral-domain optical coherence tomography (SD-OCT)
Description
Evaluation of retinal characteristics
Time Frame
28 days after last dose administration
Title
Fluorescein angiography (FA)
Description
Evaluation of retinal vasculature
Time Frame
28 days after last dose administration
Other Pre-specified Outcome Measures:
Title
Spectral-domain optical coherence tomography
Description
Changes in retinal thickness and relative changes (%) in CNV lesion area (mm2)
Time Frame
Week 24 for Part A and Week 32 for Part B
Title
Fluorescein angiography
Description
Changes in retinal fluid and relative changes (%) in CNV lesion area (mm2)
Time Frame
Week 24 for Part A and Week 32 for Part B
Title
Cmax
Description
Peak plasma concentration of OLX10212
Time Frame
Day 0, Day 1, Day 2, and Day 3 for Part A and Day 0, Day 1, Day 2, Day 3, Day 28, Day 29, Day 30, Day 56, Day 57, Day 58, and Day 59 for Part B
Title
Tmax
Description
Time at which Cmax occurs
Time Frame
Day 0, Day 1, Day 2, and Day 3 for Part A and Day 0, Day 1, Day 2, Day 3, Day 28, Day 29, Day 30, Day 56, Day 57, Day 58, and Day 59 for Part B
Title
AUC
Description
Total area of plasma concentration of OLX10212
Time Frame
Day 0, Day 1, Day 2, and Day 3 for Part A and Day 0, Day 1, Day 2, Day 3, Day 28, Day 29, Day 30, Day 56, Day 57, Day 58, and Day 59 for Part B

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and women ≥50 years of age Primary subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea, as evidenced by FA in the study eye CNV must be ≥50% of the total lesion size in the study eye ETDRS BCVA score ranging from 20/60 to 20/400 in the study eye Clear ocular media and adequate pupillary dilation (able to dilate pupil to ≥4 mm using standard mydriatics) in the study eye to permit good stereoscopic fundus photography Retinal thickness ≥200 μm in the macular region of the study eye as measured by SD-OCT, and active neovascular AMD, in the opinion of the Investigator Willing, committed, and able to return for all clinic visits and complete all study-related procedures Able to read (or if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or by a family member), understand, and willing to sign the informed consent form Exclusion Criteria: Any prior systemic treatment for neovascular AMD in either eye, except dietary supplements or vitamins or systemic anti-VEGF therapy, or planned use at any time during the study Any prior treatment in the study eye with another investigational agent to treat neovascular AMD within 6 months prior to Day 0 or planned use at any time during the study Prior treatment with anti-VEGF agents as follows: Anti-VEGF therapy in the study eye within 4 weeks prior to Day 0 Anti-VEGF therapy in the study eye at any time to which there was no response, as defined by the presence of at least 1 of the following conditions: (1) persistent (plasma) fluid exudation, (2) unresolved or new hemorrhage, and (3) progressive lesion fibrosis Anti-VEGF therapy in the fellow eye with an investigational agent (not FDA approved, unless it is bevacizumab) within 3 months prior to Day 0 (prior treatment with an FDA approved anti-VEGF therapy in the fellow eye is allowed at any time) Systemic anti-VEGF therapy, investigational or FDA approved, within 3 months prior to Day 0 or planned use at any time during the study Scar or fibrosis in the study eye involving >50% of the total lesion size Retinal pigment epithelial tears or rips in the study eye involving the macula within 6 months prior to Day 0 History of any vitreous hemorrhage in the study eye within 4 weeks prior to Day 0 Presence of other causes of CNV in the study eye, including pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis Clinical evidence of moderate or severe diabetic retinopathy, diabetic macular edema, or any other inflammatory or occlusive vascular disease affecting the retina (other than AMD) in either eye History of stage ≥2 macular hole in the study eye Any prior intraocular or periocular surgery on the study eye within 3 months prior to Day 0 (lid surgery is allowed if it took place at least 1 month prior to Day 0 and is unlikely to interfere with OLX10212 injection). Prior vitrectomy in the study eye, surgery for retinal detachment in the study eye, and prior trabeculectomy or other filtration surgery in the study eye are not permitted at any time Uncontrolled glaucoma (defined as IOP ≥25 mmHg despite treatment with antiglaucoma medication) in the study eye Glaucoma in the study eye requiring treatment with 3 or more antiglaucoma medications Active intraocular inflammation or history of uveitis in either eye Presence or history of ocular or periocular infection in either eye within 2 weeks prior to Day 0 Presence of scleromalacia in the study eye Aphakia or absence of posterior capsule in the study eye (unless due to yttrium aluminum garnet [YAG] posterior capsulotomy) Prior therapeutic radiation in the region of the study eye or planned use at any time during the study Significant media opacities, including cataract, in the study eye that, in the opinion of the Investigator, could interfere with visual acuity, assessment of safety, or fundus photography Any concurrent intraocular condition in the study eye (eg, cataract) that, in the opinion of the Investigator, could (1) require either medical or surgical intervention during the 24- or 32-week study period (Part A or Part B, respectively), (2) increase the risk to the patient beyond what is to be expected from standard intraocular injection procedures, or (3) otherwise interfere with the injection procedure or efficacy or safety evaluation History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications Participation as a patient in any clinical study or prior systemic or ocular treatment with an investigational agent within 12 weeks prior to Day 0 Prior systemic or intraocular treatment with long-acting steroids within 6 months prior to Day 0 or planned use at any time during the study History of allergy to povidone iodine Known allergy to fluorescein sodium for injection in angiography Unwillingness among females who are pregnant, breastfeeding, or of childbearing potential to practice adequate contraception throughout the study. Adequate contraceptive measures include oral contraceptives (stable use for ≥2 cycles prior to Day 0), intrauterine device, Depo-Provera® (Pfizer, Inc., New York) or Norplant System® (Pfizer, Inc., New York) implants, bilateral tubal ligation, vasectomy, and condom or diaphragm plus contraceptive sponge, foam, or jelly. A female is considered to be of childbearing potential unless she is premenstrual, 1 year postmenopausal, or 3 months post-surgical sterilization. All females of childbearing potential, including those with post-tubal ligation, must have a negative urine pregnancy test result at Day 0 and every 4 weeks as outlined in the Schedule of Activities. A negative serum pregnancy test must be obtained at Screening.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kyungah Hong, MS
Phone
+82 31-779-8400
Email
kahong@olixpharma.com
First Name & Middle Initial & Last Name or Official Title & Degree
Eunah Park, MS
Phone
+82 31-779-8400
Email
eunah.park@olixpharma.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander Neumeister, MD
Organizational Affiliation
Olix Pharmaceuticals, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
California Retina Consultants
City
Santa Maria
State/Province
California
ZIP/Postal Code
93434
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mary Lopez-Isidro
Email
mary.lopez-isidro@californiaretina.com
First Name & Middle Initial & Last Name & Degree
Daniel Learned, MD
Facility Name
University Retina
City
Oak Forest
State/Province
Illinois
ZIP/Postal Code
60452
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
BreAnne Kirby
Email
bkirby@uretina.com
First Name & Middle Initial & Last Name & Degree
Veeral Sheth, MD
Facility Name
The Retina Institute
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63128
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lauren McDonald-Mueller
Email
lauren.mcdonald-mueller@rc-stl.com
First Name & Middle Initial & Last Name & Degree
Athanasios Papakostas, MD
Facility Name
Ophthalmic Consultants of the Capital Region
City
Troy
State/Province
New York
ZIP/Postal Code
12180
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kathy McNulty
Email
kmcnulty@ophthalmicconsultants.com
First Name & Middle Initial & Last Name & Degree
Robert Feldman, MD
Facility Name
Texas Retina Consultants
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Cormier
Email
jessica.cormier@retinaconsultantstexas.com
First Name & Middle Initial & Last Name & Degree
Charles Wykoff, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27427487
Citation
Hwang J, Chang C, Kim JH, Oh CT, Lee HN, Lee C, Oh D, Lee C, Kim B, Hong SW, Lee DK. Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. J Invest Dermatol. 2016 Nov;136(11):2305-2313. doi: 10.1016/j.jid.2016.06.626. Epub 2016 Jul 15.
Results Reference
background

Learn more about this trial

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

We'll reach out to this number within 24 hrs